Who We Are
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies designed to improve patient outcomes. We have developed and own multiple intellectual properties (IPs) in detection and quantitation of metabolites.
We hand-picked a proven, global enterprise team of scientists, engineers and medical professionals to help commercialize our innovative technology and to increase prediction and accuracy in the diagnosis of cancers by following and incorporating the highest regulatory, clinical and scientific standards.
Our cross pollinated, balanced and committed team was established in 2007. Our mission is to develop and commercialize innovative technologies to increase prediction and accuracy in diagnosis of cancers.